ESMO News

FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma

noreply@esmo.org — Wed, 22 Jul 2026 07:07:00 +00:00

Evidence for efficacy is based on the results from the LITESPARK-022 study

Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence

noreply@esmo.org — Tue, 21 Jul 2026 07:07:00 +00:00

Findings from the LITESPARK-022 study

Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and Advertising Legislation

noreply@esmo.org — Mon, 20 Jul 2026 07:07:00 +00:00

Given that up to 40% of all cancers are preventable, robust tobacco cessation policies are among the most effective strategies for reducing the risk of cancer, improving human health, and reducing cancer cases

Temporary Interruption of Endocrine Therapy for Pregnancy, Including Use of Fertility Preservation, Does Not Increase Risk of Breast Cancer Events in Women with HR-positive Breast Cancer

noreply@esmo.org — Mon, 20 Jul 2026 07:07:00 +00:00

Updated findings from the POSITIVE study

EMA Recommends Extension of Therapeutic Indications for Pembrolizumab

noreply@esmo.org — Fri, 17 Jul 2026 07:07:00 +00:00

New indications concern treatment of adult patients with resectable muscle invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy and treatment of adolescents with melanoma and relapsed or refractory classical Hodgkin lymphoma

CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas

noreply@esmo.org — Thu, 16 Jul 2026 07:07:00 +00:00

Findings from 10-year follow-up of a phase II study

ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care

noreply@esmo.org — Wed, 15 Jul 2026 07:07:00 +00:00

ESMO hails the publication of the WHO Global Status Report on Cancer, a reference for policymakers, healthcare professionals, patient organisations and other stakeholders working to improve cancer outcomes worldwide.

The European Parliament’s Reports Include Several ESMO Asks and Materially Strengthen the European Commission Proposals Under the ‘Health Package’

noreply@esmo.org — Wed, 15 Jul 2026 07:07:00 +00:00

Proposed changes to the EU in vitro diagnostic medical devices (IVDR) legislation, and the EU Biotech Act I, help address key ESMO concerns on fragmented procedures, lower-risk testing, central laboratories and multinational oncology studies, ensuring more equitable access to innovative oncology treatment for all patients with cancer

FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer

noreply@esmo.org — Wed, 15 Jul 2026 07:07:00 +00:00

It also approved a companion diagnostic device

Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC

noreply@esmo.org — Tue, 14 Jul 2026 07:07:00 +00:00

Findings after 7 years of follow-up in the CROWN study

GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes

noreply@esmo.org — Mon, 13 Jul 2026 07:07:00 +00:00

Findings from a large real-world cohort

EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan

noreply@esmo.org — Fri, 10 Jul 2026 07:07:00 +00:00

New indication concerns monotherapy for patients with advanced TNBC who have not received prior systemic treatment for metastatic disease and who are not candidates for PD-(L)1 inhibitors

Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma

noreply@esmo.org — Thu, 09 Jul 2026 07:07:00 +00:00

Findings from the SUCCESSOR-2 study

FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer

noreply@esmo.org — Wed, 08 Jul 2026 07:07:00 +00:00

Evidence for efficacy is based on the results from the POTOMAC study

Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers

noreply@esmo.org — Tue, 07 Jul 2026 07:07:00 +00:00

Findings from an observational cohort study

Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026

noreply@esmo.org — Mon, 06 Jul 2026 15:07:00 +00:00

ESMO is pleased to announce a call for applications for the position of Editor-in-Chief for three new journals that will join the Society’s growing portfolio of oncology publications in 2026

Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence Over Tamoxifen and Further Reduction Is Seen When Combined with Exemestane

noreply@esmo.org — Mon, 06 Jul 2026 07:07:00 +00:00

Findings from the SOFT and TEXT studies

Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery

noreply@esmo.org — Fri, 03 Jul 2026 14:07:00 +00:00

A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026

EMA Recommends Extension of Therapeutic Indications for Encorafenib

noreply@esmo.org — Fri, 03 Jul 2026 07:07:00 +00:00

New indication concerns a combination with cetuximab and FOLFOX for the first-line treatment of patients with metastatic CRC with a BRAF V600E mutation

New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer

noreply@esmo.org — Thu, 02 Jul 2026 14:07:00 +00:00

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026